CVRx, Inc. (CVRX)
NASDAQ: CVRX · IEX Real-Time Price · USD
8.29
+0.21 (2.60%)
At close: May 17, 2024, 4:00 PM
8.10
-0.19 (-2.29%)
After-hours: May 17, 2024, 5:36 PM EDT
Company Description
CVRx, Inc., a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases.
The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.
It sells its products through direct sales force, as well as sales agents and independent distributors in the United States, Germany, and internationally.
The company was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
CVRx, Inc.
Country | United States |
Founded | 2000 |
IPO Date | Jun 30, 2021 |
Industry | Medical Devices |
Sector | Healthcare |
Employees | 200 |
CEO | Kevin Hykes |
Contact Details
Address: 9201 West Broadway Avenue, Suite 650 Minneapolis, Minnesota 55445 United States | |
Phone | (763) 416-2850 |
Website | cvrx.com |
Stock Details
Ticker Symbol | CVRX |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
IPO Price | $18.00 |
CIK Code | 0001235912 |
CUSIP Number | 126638105 |
ISIN Number | US1266381052 |
SIC Code | 3841 |
Key Executives
Name | Position |
---|---|
Kevin Hykes | President, Chief Executive Officer and Director |
Jared Oasheim | Chief Financial Officer |
Paul Verrastro | Chief Marketing and Strategy Officer |
Paul Pignato | Vice President of Operations |
Jonelle R. Burnham | Vice President and General Counsel |
Craig Palmer | Senior Vice President of US Sales |
Latest SEC Filings
Date | Type | Title |
---|---|---|
May 16, 2024 | SD | Form - SD |
May 10, 2024 | 10-Q | Quarterly Report |
Apr 30, 2024 | 8-K | Current Report |
Apr 23, 2024 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
Apr 23, 2024 | DEF 14A | Other definitive proxy statements |
Apr 11, 2024 | PRE 14A | Other preliminary proxy statements |
Feb 20, 2024 | 144 | Filing |
Feb 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |
Feb 9, 2024 | 10-K | Annual Report |